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BlaC, the single chromosomally-encoded β-lactamase of Mycobacterium tuberculosis, has been 
identified as a promising target for novel therapies that rely upon β-lactamase inhibition. Boronic 
acid transition state inhibitors (BATSIs) are a class of β-lactamase inhibitors which permit 
rational inhibitor design by combinations of various R1 and R2 side chains. To explore the 
structural determinants of effective inhibition, we screened a panel of 25 BATSIs to explore key 
structure-function relationships. We identified a cefoperazone analogue, EC19, which displayed 
slow, time-dependent inhibition against BlaC with a potency similar to clavulanate. To further 
characterize the molecular basis of inhibition, we solved the three-dimensional structure of the 
EC19-BlaC complex and expanded our analysis to variant enzymes. The results of this structure-
function analysis encourage the design of a novel class of β-lactamase inhibitors, BATSIs, to be 
used against Mycobacterium tuberculosis. 
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Currently, four-drug regimens are the cornerstone of treatment against infections with 
Mycobacterium tuberculosis (Mtb) achieving cure rates that approach 95% (1-3). Unfortunately, 
therapeutic challenges arise as a result of drug resistance. Due to the long treatment duration and 
the ability of Mycobacteria spp. to readily adapt to changes in their microenvironment, the 
emergence of resistance is inevitable. Against multi-drug resistant (MDR) and extensively drug 
resistant (XDR) strains of Mtb, chemotherapeutic choices are limited and new options are being 
sought (4). The concurrence of infection by Human Immunodeficiency Virus, HIV, and Mtb 
create a serious global challenge. Recent progress in antiretroviral therapy is hampered by 
increasing frequence of drug resistant strains of Mtb. 
Presently, β-lactams, and their combination with β-lactam inhibitors, are being explored 
for the treatment of Mtb. The chromosomal β-lactamase, BlaC, is responsible for resistance to β-
lactam antibiotics of multiple classes (5, 6). BlaC, which is capable of inactivating a broad range 
of penicillins and cephalosporins, belongs to Ambler class A, members of which usually being 
susceptible to inhibitors such as clavulanic acid (6). Indeed, the combination of meropenem and 
clavulanate was found to be effective in sterilizing Mtb cultures, including XDR strains (7). 
Furthermore, BlaC appears to be intolerant of substitutions that alter substrate profiles and confer 
resistance to clavulanic acid inactivation (8). Notwithstanding, a detailed understanding of 
structural determinants of effective inhibition may lead to development of more potent inhibitors.  
Based upon these considerations, we anticipate that novel β-lactamase inhibitors that possess 
favourable pharmacodynamic and pharmacokinetic properties will be effective against BlaC and 
will play an important role in treating drug-resistant Mtb infections in the near future (9). 
Boronic acid transition state inhibitors (BATSIs) are a class of β-lactamase inhibitors, 
which have been studied and optimized for a variety of β-lactamase enzymes (10-15). By 
binding covalently to the active site nucleophile of the enzyme, the boronate adduct sterically 
and electronically resembles the tetrahedral high-energy intermediate of the β-lactam hydrolysis 
reaction. Such inhibitors have been shown to complex the active site and lead to inhibition in a 
reversible, competitive manner (Scheme 1). BATSIs can be synthesized so they possess a side-
group which resembles R1 side-chains of known β-lactams necessary for specific interaction 
with the enzyme. Variation of this side-chain and the optional addition of an R2 group allow a 
rational inhibitor design (16). 
In order to further elucidate the structural basis of effective inhibition, we used BATSIs to 
probe the active site of BlaC of Mtb. To this end, we tested a select panel of 25 BATSI 
compounds that carry different combinations of R1 and R2 side groups (Scheme 2), seven of 
which were newly synthesized. We determined key structural elements necessary for effective 
inhibition. We next expanded our analysis to variant enzymes with alterations in the carboxylate-
binding regions. Our findings reveal that select BATSIs are effective biochemical inhibitors of 
BlaC, however they rely on productive interactions with the carboxylate binding region of the 
enzyme. These results allow for the potential design of a novel class of β-lactamase inhibitors to 
be used in the treatment of Mtb and expand our repertoire of possible compounds to be used in 
therapy. 
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RESULTS AND DISCUSSION 
 
The design strategy employed here started with the two reference compounds shown in Figure 1. 
The acetyl group of 1 was systematically replaced with R1 substituents present on the β-lactam 
ring of active penicillin and cephalosporin-like antibacterials (compounds 3-21). In addition a 
small number of ureido- and sulfonamido- derivatives were prepared (compounds 22-25). These 
starting compounds were then further derivatized with one or two homologous meta-benzoic acid 
substituents (R2) to mimic the carboxylate group present on the larger heterocyclic fused ring of 
all β-lactam antibiotics. Finally, in the cefoperazone series, various phenolic, catecholic and 
aniline rings were introduced as substituents of the phenolic group of the R1 side chain.  
The enzyme inhibition by BATSIs is posited to follow slow-reversible kinetics. Based on 
structural data, the model is represented according to the following equation (1): 
 
E + I ↔ E:I ↔ E-I≠ ↔ E-I≠≠ (1) 
 
where E stands for β-lactamase enzyme, I for inhibitor, E:I for the Michaelis complex, E-I≠ for 
enzyme-inhibitor complex resembling the acylation high-energy intermediate, and E-I≠≠ the de-
acylation high-energy intermediate, respectively. This model takes into account the 
crystallographic intermediates captured in SHV-1 (12), CTXM-9 and CTXM-14, respectively 
(13). Using the highly chromogenic nitrocefin as substrate, we screened these 25 compounds 
both under initial velocity conditions and after 5 minute pre-incubation with BlaC. Inhibitor 
concentrations that reduce the substrate reaction by 50% were determined and expressed as Ki 
values for immediate inhibitiory activity, and Ki* values following 5 minutes pre-incubation.  
Both reference compounds 1 and 2 were devoid of inhibitory activity. 
We identified eight with inhibitory activity, of which five inhibited BlaC at 
concentrations less than 5 µM.  Almost all of these active inhibitors contained a meta-benzoic 
acid R2 substituent. The only exception was the cefotaxime analog, compound 11; in our 
experiments this BATSI was a rapid onset inhibitor whose Ki value was 5.5 ± 0.3 µM, and only 
decreased to Ki* of 4.1 ± 0.3 µM after a five minute incubation with BlaC. All other seven active 
compounds revealed negligible activity when testing the inhibition immediately following BlaC 
addition, but revealed inhibition after a 5 minute pre-incubation with enzyme. The only penicillin 
analog with activity was the ampicillin analog, compound 3, which possessed the benzoic acid 
R2 substituent. Of the cephalothin analogs, both compounds 9 and 10 showed activity. Both 
compounds also have benzoic acid R2 substituent, either directly attached to the boron-bearing 
carbon atom, or with a methylene spacer for additional flexibility. The ceftazidime analog, 
compound 13, was a relatively weak inhibitor. 
 Of the eight cefoperazone analogs, only compounds 20 and 21 showed inhibitory activity 
after a five minute incubation with BlaC. This series explored different phenolic, catecholic and 
aniline substituents to evaluate whether changing the stereochemistry (compound 16) and side 
chain length (compounds 15 and 17) influenced inhibitory activity. Compounds 20 and 21, like 
those in the cephalothin series, differed only in the spacing of the benzoic acid R2 substituent 
with respect to the boron atom. In this case, however, the added methylene group reduced the Ki* 
value five-fold, while in the cephalothin series, the opposite behavior was observed. Compound 
21, which we term EC19, exhibited the lowest Ki* value of all the BATSIs, with a measured Ki* 
value of 0.65 ± 0.05 µM. 
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 Finally, a small number of ureido- and sulfonamido-containing boronic derivatives were 
prepared and evaluated. Only the ureido- compound 23 exhibited inhibitory activity. Neither 
sulfonamide compound (24 and 25) exhibited activity, including compound 25 which contains 
the benzoic acid R2 substituent. However, these compounds are known to adopt a different 
orientation of the R2 substituent when bound to the AmpC β-lactamase (17).  
 From these studies, we can make several general comments. Firstly, there is a clear and 
strong improvement in inhibition when there is a benzoic acid as the R2 substituent; we postulate 
that this group interacts with BlaC where the conserved carboxyl group present in all β-lactams 
binds. It is also clear that the presence of this substituent in the inhibitors induces time-dependent 
inhibitor kinetics that is not observed with the single inhibitory compound lacking this feature 
(compound 11). Secondly, the nature of the R1 substituent influences, but is not the main driver 
of inhibitory activity. Different R1 groups were present in five different inhibitor series. 
 Our results are quite different from other reports of BATSI inhibition of other Class A and 
C β-lactamases. In the case of the Acinetobacter-derived ADC-7 cephalosporinase (15), the 
achiral cephalothin showed favorable inhibitory activity that was enhanced by the addition of a 
phenyl group in the R2 position. Similar observations have been reported for the TEM-1 β-
lactamase (10). In the case of TEM-1, an aromatic R2 substituent allows for a favorable π-π 
stacking interaction with the Tyr105 phenolic ring (10). A tyrosine residue is found in the 
equivalent position in many Class A β-lactamases (18, 19). The KPC-2 carbapenemase has a 
tryptophan at the equivalent position that similarly stacks with aromatic substituents (20). The 
structures of a large number of BlaC-substrate and -inhibitor complexes reveals that aromatic 
amino acid side chains are not present in the active site at an equivalent position. This position is 
occupied by an isoleucine residue instead, which may explain the lack of activity of compound 7. 
Rather, we believe that the effectiveness of the benzoic acid substituted BATSIs as BlaC 
inhibitors reflects their binding at the “carboxylate binding region” of the active site. This may 
differentiate BlaC from other Class A enzymes. In the crystal structure of BATSI covalently 
bound with the SHV-1 β-lactamase (12), the R1 substituent is found in an orientation in which it 
interacts with the carboxylate binding region.  
 To this end, we tested the inhibitory effectiveness of compound 21 (EC19) as inhibitor of 
variant forms of BlaC that possessed changes in the carboxylate binding pocket. In all previously 
characterized Class A β-lactamases, this region is repesented by a K234-T235-G236 sequence 
motif (“KTG motif”) and a nearby arginine residue, R244 (21). In BlaC, the R244 is replaced 
with an alanine (A244). It was first shown for the TEM-1 β-lactamase, that this positive charge 
could be replaced by arginine residues located proximally to R244 (22). In the case of BlaC, the 
function of R244 is served by R220 which provides the necessary positive charge and 
electrostatically interacts with the negatively charged carboxylate of the β-lactam substrates (8). 
To investigate whether the R2 meta-benzoic acid substituent interacts with the carboxylate 
binding region of BlaC, we tested the inhibition of nitrocefin hydrolysis by the R220A, R220S 
and doubly substituted β-lactamase R220A, A244R (Table 2). These variants were constructed to 
investigate the impact of the positive charge (R220A, R220S) by relocalizing the positive charge 
from position 220 to 244. As a control, we also measured inhibition with the S130G variant 
enzyme which exhibits similar kinetic properties to the other variants but maintains the “native” 
carboxylate binding motif. Interestingly, we found that compound 21 is ineffective at inhibiting 
the R220A and R220S variants of BlaC, yet retains potent inhibition against both the doubly 
substituted β-lactamase where the positive charge has been repositioned from residue 220 to 
residue 244 and the S130G BlaC retaining the native carboxylate binding site. These data argue 
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that the meta-benzoic acid R2 substituent binds as a mimic of the substrate carboxylate. Further, 
these observations may point towards a potential mechanism to develop resistance against 
BATSI compounds. 
 
 Essentially, almost all of the active BATSIs exhibit time-dependent inactivation, a 
behavior that has been previously observed for other β-lactamases when inhibited with BATSIs 
that carry a stereogenic center (23, 24). In order to investigate this more thoroughly, we 
performed experiments in which the hydrolysis of nitrocefin by BlaC was determined as a 
function of inhibitor concentration, focusing upon EC19 (compound 21). As seen in Figure S1A, 
the initial rates are approximately similar at various EC19 concentrations, but after 150-200 
seconds the rates begin to decrease and, at higher concentrations, the reaction rates approach 
zero. These data were fit to a model where the inhibitors bind to the free BlaC and form an initial 
Michaelis complex, which then isomerizes in a slow step to generate a second complex. Using 
equation 4, we could calculate from these data values for kon of 0.001 µM
-1s-1 and koff of 0.0013 
sec-1 (our chemical interpretation of this kinetic model will be discussed below). To test whether 
this time dependency also applied to dissociation of the inhibitor from the complex, and to 
ensure the covalent complex was reversibly formed, we formed the complex (10x the Ki*) and 
tested for inhibitor release and regain of activity by diluting the complex 100-fold before adding 
nitrocefin to initiate the reaction. Using EC19, the reaction rate increased slowly, consistent with 
a reversible but very slow dissociation rate (Figure S2A). In contrast, when this experiment was 
performed with LP08 (compound 11), the rate of hydrolysis of nitrocefin was essentially equal to 
the control reaction, where inhibitor was not added (Figure S2A). These kinetic results support 
our proposal that the time-dependence of BATSIs containing the meta-benzoic acid R2 
substituent is due to this binding and subsequent isomerization both in the association and 
dissociation reactions.  
 
 Finally, the influence of the R1 substituent on inhibitory potency is not mirrored in the 
efficiency of the corresponding β-lactam as substrate for BlaC. Penicillins are in general better 
substrates for BlaC than cephalosporins (6, 25). For example, ampicillin exhibits a Km value of 8 
µM (6, 25), yet compound 3 exhibits one of the highest Ki* values of all active compounds 
tested. Cephalothin exhibits a Km value of 150 µM; however compound 10 exhibits a Ki* value 
of 2.7 ± 0.2 µM. Finally, cefotaxime exhibits a Km value of 5.5 mM, yet compound 11 exhibits a 
Ki* value of 5.5 ± 0.3 µM. Similar observations have been reported for the Class A extended 
spectrum β-lactamase CTX-M: the most potent BATSI inhibitor contained the R1 substituent of 
ceftazidime, one of the enzymes least favorable substrates (13). To see if this observation holds 
true for BlaC and cefoperazone, we evaluated cefoperazone as a substrate for BlaC: We did not 
detect any hydrolysis when testing concentrations up to 100 µM. Further, we tested to see 
whether this compound was a “slow substrate” for BlaC and thus an inhibitor of nitrocefin 
hydrolysis. Cefoperazone at a concentration of 10 µM did not inhibit nitrocefin hydrolysis.  We 
hypothesize that the rigid structure of cefoperazone, with the dihydrothiazine ring fused to the β-
lactam ring, may prevent the optimal interaction of both the carboxylate and the R1 substituent. 
In the case of the BATSI inhibitors described here, the meta-benzoic acid R2 substituent and R1 
diketopiperazine are connected by bonds that allow for free rotation of the two groups, thus 
allowing for optimal alignment and interaction within the BlaC active site. In this setting, the 
more complex R1 substituents of the cephalosporins may allow for more specific interactions 
with BlaC that complement the interaction of the β-lactam carboxylate with the carboxylate 
Page 6 of 25
ACS Paragon Plus Environment
ACS Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
binding site. In a broader view, BATSI inhibitors are not mimicking the natural substrate of the 
enzyme, but rather the high energy intermediate product of the enzymatic reaction. 
 
Crystal structure 
Co-crystallisation of wild type BlaC with EC19 was prevented by the dissolution of the crystal in 
DMSO containing inhibitor solution. However, the compound was successfully trapped in the 
N172A variant protein which additionally resulted in bigger crystals and the structure was 
resolved at 1.4 Å. There was clear electron density between the Ser70 hydroxyl side chain and 
the boron atom in the boronate covalent complex of EC19 and BlaC. All three rings of the 
inhibitor were able to be unambiguously mapped and Figure 2A shows the model of the bound 
complex surrounded by the experimental electron density, contoured at 2σ. 
  
One of the boronate oxygen atoms interacts with the amide nitrogens of Ser70 and 
Thr237 (Figure 2B). These two residues constitute the “oxyanion hole” that stabilizes the 
formation of the anionic, tetrahedral intermediate during β-lactam hydrolysis (Scheme 1). The 
other boronate oxygen occupies the position where the conserved hydrolytic water molecule 
normally is located. The boronate oxygen atom makes a hydrogen bonding interaction with 
Glu166, the base normally responsible for activating the water molecule in the deacylation 
reaction. The diketopiperazine substituent (R1) makes several interactions with active site 
residues. The two ketones are positioned by hydrogen bonding to the amide backbone nitrogens 
of Ser104 and Arg103 while the nearby exocyclic carbonyl interacts with the side chain of 
Arg171. The central phenol ring points out into solvent and makes a hydrogen bonding 
interaction with a water molecule. The meta-benzoic acid R2 substituent similarly points out 
toward solvent and makes no interactions with the enzyme. However, clearly defined electron 
density is observed in the complex where the carboxylate of other β-lactam complexes normally 
binds. We have modelled this as a phosphate anion in Figure 2B, since the crystallization 
solution contains 2 M sodium phosphate and this phosphate anion has been observed at this 
position in the apo-BlaC structure (PDB entry 2GDN).  
Based on this additional electron density, we advance that in solution, the binding of 
EC19, and other similarly substituted inhibitors, is driven by the interaction of the carboxyl 
group with R220 and T235, residues that make up the carboxylate binding site. We could obtain 
a reasonable model of that interaction by simply rotating the methylene group of the meta-
benzoic acid substituent to optimize the interaction between the carboxyl group and R220 and 
T235 (Figure 3). This generates two quite reasonable hydrogen bonds at distances of 2.3 and 2.6 
Å, respectively. We propose, based on the nature and strength of the inhibition by the inhibitor 
series studied here, that the initial interaction between EC19 and the enzyme is driven by the 
binding of the meta-benzoic acid group into the carboxyl binding site. This interaction is similar 
to the formation of a pre-catalytic Michaelis complex for substrates and positions the boronate 
atom in proximity to S70 which, after deprotonation by K73, adds as a nucleophile to the boron 
atom to generate the covalent enzyme-inhibitor complex. The two boronate oxygen atoms 
interact with the oxyanion hole residues and the E166 catalytic base in the deacylation reaction. 
This is followed by the interaction of the diketopiperazine substituent with the amide backbone 
nitrogens of R103 and S104 and of the carbonyl group with R171. In solution, it is likely that the 
meta-benzoic acid substituent remains bound at the carboxylate binding site, and that the 
alternate inhibitor conformation that we observe in the crystal is likely due to the very high 
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concentration of phosphate in the crystallization buffer solution and the inability of the EC19 
benzoic acid substituent to displace it. 
  
Conclusion:  
We show here that BATSIs can be used as molecular probes to investigate the structural basis of 
inhibition of BlaC, an important drug target against otherwise drug resistant strains of 
tuberculosis. Our major observation is that in addition to a R1 group, the meta-benzoic acid 
substituent in R2 position is necessary for effective inhibition of BlaC, as it provides productive 
interactions with the carboxylate binding region of the enzyme. Compound 21 (EC19) was found 
to have a  Ki* of 0.65µM, which is lower than corresponding values for currently available 
inhibitors (we have determined the IC50 of clavulanate, sulbactam, and tazobactam as 1.7 ± 0.2, 
1.6 ± 0.2, and 2.5 ± 0.2 µM, respectively (8)). This is the first description of a BATSI inhibitor 
against BlaC. EC19 may serve as an important lead compound for the rational design of more 
potent inhibitors. With the insights obtained by this structure-function study, we are confident 
that further optimisation can be reached. 
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METHODS: 
BlaC purification 
The blaC genes carrying a truncated sequence of BlaC cloned in a pET28 based plasmid was 
expressed in E. coli BL21(DE3) and purified; the correct size was confirmed by mass 
spectrometry as previously described (6, 8). Variant enzymes were generated using site-directed 
mutagenesis as reported (8, 26). Protein concentrations were determined measuring absorption at 
280nm at various dilutions using an Eppendorf BioPhotometer plus (Eppendorf AG Hamburg, 
Germany). 
 
BATSI synthesis 
BATSIs were chemically synthesized by acylation of aminomethaneboronate with suitable 
commercially-available R1-carboxylic acids. Chiral BATSIs were obtained in enantiomerically 
pure form by stereoselective homologation of (+)-pinanediol 3-carboxyphenyl-methaneboronate 
followed by substitution, acylation and final deprotection at the boronic and carboxylic 
functionalities. The general scheme for the synthesis of these compounds is summarized in 
Scheme 2 and experimental details for the synthesis of BATSIs are reported in Supplementary 
Material (Compounds 2, 5, 8, 18, 20, 22 and 23) or elsewhere (see Table 1). 
 
Kinetic measurements 
 Steady state kinetics were performed on an Agilent 8453 diode array spectrophotometer 
(Palo Alto, CA) in Na-Phosphate buffer at room temperature (50 mM, pH 7.2) and a 1cm path 
length cuvette as previously detailed. Nitrocefin (NCF) was used as substrate with the extinction 
coefficient ∆ε =17,400 M-1cm-1 at 482 nm. Inhibitor kinetics were performed with NCF as the 
reporter substrate at 100 µM concentration. BATSIs follow reversible inhibition kinetics. 
Increasing concentrations were used to determine the specific concentration Ki that reduces 
initial NCF hydrolysis reaction by 50%. For each concentration reactions were performed in 
triplicates and the average velocity was used. Results were corrected for NCF affinity using 
equation (2): 
 
Ki(corrected) = Ki(obs)/(1 + [NCF]/KmNCF)  (2) 
 
Kinetic parameters for BlaC and the reporter substrate NCF were previously determined as Km 
56 µM and kcat 72 sec
-1 (8). This corresponds to a correction factor of 0.36.  
 In a first screen, 50 μM of inhibitor were used to determine compounds with the ability to 
reduce the initial velocity of nitrocefin hydrolysis by BlaC by 50%, which would correspond to a 
“Ki corrected” of 20 μM or less. For all compounds, initial velocities were obtained within 5 
seconds and after 5 minutes pre-incubation. For compounds that possess a stereogenic center on 
the boron-bearing carbon atom we gererally observed slow, reversible inactivation resulting in a 
substantial increase in inhibition after 5 minute pre-incubations. For compounds which reduced 
initial velocities by at least half, formal determination of Ki (immediate) and Ki* (5 minutes pre-
incubation), respectively, was performed. The results are summarized in Table 1. 
 
 In select cases (i.e., compound 21 (EC19)), testing for reversibility of inhibition was 
performed as follows: 0.05 µg BlaC was incubated in total of 10 µl buffer with the inhibitor at 
concentration equal to 10 x Ki* for 20 min. Then, the whole reaction mix was added to 990 µl 
buffer solution containing 100µM NCF, equal to 1:100 dilution of inhibitor (0.1 x Ki*). The 
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formation of the NCF product of hydrolysis over 800s was monitored and compared to a similar 
experiment without inhibitor.  
 For EC19, association and dissociation rate constants (kon and koff, respectively) were 
determined as follows: Product formation was monitored over time in the presence of EC19 in 
increasing concentrations using 0.05 µg BlaC and 100 µM NCF. The data were fitted to equation 
3 using Origin 8.0 (OriginLab, Northampton, MA) to obtain the apparent rate constant kobs, 
which reflects the rate for conversion from initial velocity (vi) phase to steady state velocity (vs), 
with A(t) indicating absorbance at reaction time t, and A0 initial absorbance, respectively: 
 
A(t) = A0 + vst+(vi-vs)/kobs*[1-exp (-kobst)]   (3) 
 
For simple (one step) reversible binding to BlaC, kobs is a linear function of inhibitor 
concentration (eq. 4), with:  
 
kobs = kon[I] + koff    (4). 
 
Thus, koff is the y(0) intercept, and kon is derived from the slope kobs/[I], corrected for affinity (eq. 
5)(27): 
kon = kobs/[I]*(1+[S]/Km)    (5) 
 
An inhibition screen with two compounds (20µM) was performed for the BlaC variant enzymes 
R220A, R220S, R220A-A244R and S130G in order to determine the impact of the carboxylate 
binding site (8). The results are summarized in Table 2. 
 
Crystallography 
The method of hanging drop vapour diffusion was used for crystallization of N172A mutant 
BlaC. The composition of the well consists of 0.1 M HEPES, pH 7.5 and 2 M NH4H2PO4, which 
makes the final pH of the well solution, 4.1. Protein at a concentration of 14 mg/ml was mixed 
1:1 with the well solution and incubated at 10 °C. The N172A BlaC was initially seeded with the 
native enzyme crystals (BlaC) and then after iterative crystal seeding, the pure mutant crystals 
were obtained. Iterative micro-seeding resulted in efficient crystal growth as well as improved 
morphology and finally produced diffraction quality crystals of the mutant enzyme. N172A 
crystals were solved in same space group (P212121) as the wild type and were bigger in size.  
 
Data Collection and Refinement: EC19 is insoluble in water, but soluble in DMSO. A DMSO 
solution of 500 mM EC19 was used as a stock solution and serially diluted with equal volume of 
water for three rounds of soaking. This diluted DMSO solution (containing about 65 mM EC19) 
was used for soaking experiment with N172A variant BlaC. After placement in the soaking 
solution, the crystals were frozen in liquid nitrogen in time intervals of 15 minutes, 30 minutes, 
1, 2, 4, 6, 12, 24 and 48 hours respectively. Mineral oil was added to the solution as a cryo-
protectant. Diffraction data were collected from each of the single frozen crystals using a 
RAXIS-IV++ detector mount on a Rigaku RH-200 rotating anode (copper anode) X-ray 
generator. While no or insufficient electron density of the ligand was observed for crystals after 
early freezing, adequate intensity was observed for crystals frozen after 24 hours of soaking. 
Data were collected at Brookhaven National Laboratory on crystals frozen after 24 hours soaking 
with EC19. Beam lines X29 were used for data collection. The data were processed using 
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HKL2000 (28). Previous structure of Mtb β-lactamase with bound NXL104 (PDB entry 4HFX) 
(29) was used to phase the data, using the CCP4 software suite (30). Multiple rounds of 
structural refinement and model building were performed in Refmac5 (31, 32), Phenix (33) and 
Coot (34). Structure figures were generated using PyMOL (The PyMOL Molecular Graphics 
System, Version 1.3, Schrödinger, LLC.) and ChemDraw Ultra 12.0 (35). Atomic coordinates 
and experimental structure factors have been deposited in the Protein Data Bank (PDB entry 
4X6T). Table 3 lists the data collection statistics for the structures as well as the final refinement 
statistics 
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Table 1: Compounds and their corresponding inhibitor constants: Ki is the inhibitor 
concentration that results in 50% velocity reduction of NCF hydrolysis, corrected for substrate 
affinity. Ki* is the corresponding concentration in µM, obtained after pre-incubation of the 
enzyme with inhibitor over 5 minutes (mean of three experiments with standard error). * 
indicates compounds that bear two, R1 and R2, side groups (compounds with a stereogenic 
center). 
Number Ref Inhibitor Ki(µM) Ki*(µM)  
 Reference compounds 
1 (11) LP03 >20 >20 
2 - EC6803 >20 >20 
 Penicillin series 
3 (36) EC25 
(Ampicillin)* 
>20 13.2 ±1.7 
4 (36) GB21 (Nafcillin) >20 >20 
5 - FP2107 (Oxacillin) >20 >20 
 Cephalothin series 
6 (16) LP04 >20 >20 
7 (16) FP2807* >20 >20 
8  - CR126* >20 >20 
9 (24) SM23* >20 1.46 ±0.2 
10 (17) EC04 >20 2.76 ±0.2 
 Cefotaxim compound 
11 (11) LP08 5.54 ±0.3 4.13 ±0.3 
 Ceftazidime series 
12 (15) LP06 >20 >20 
13 (37) MC35* >20 17.7 ±2.0 
 Cefoperazone series 
14 (12) GB0301 >20 >20 
15 (12) EC7406 >20 >20 
16 (12) EC9901 >20 >20 
17 (12) EC9701 >20 >20 
18 - EC9001 >20 >20 
19 (15) CR102 >20 >20 
20 - COBOR10* >20 3.34 ±0.4 
21 (36) EC19* >20 0.65 ±0.05 
 Ureido and sulfonamido compounds 
22 - CR48 >20 >20 
23 - FP110216* >20 7.17 ±0.4 
24 (17) CR23 >20 >20 
25 (17) CR100 >20 >20 
 
Table 2: BlaC site-directed variant enzymes:  Fractional velocities (v/v0) of NCF hydrolysis 
following 5 minutes pre-incubation with inhibitor EC19 at 20 µM concentration, in relation to 
uninhibited reaction, performed in triplicates. Note that the catalytic efficiency of the variant 
enzymes is significantly impaired compared to the wild type, with kcat/Km ratios (in µM-1 s-1) 
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for NCF of 0.01 (R220A, R220S0, 0.02 (S140G), and 0.1 (R220A, A244R), and 1.34 (wild 
type), respectively (8). S130G variant enzyme was completely inhibited by EC19. 
 EC19 (21) 
R220A 0.96 ± 0.3 
R220S 0.96 ± 0.2 
R220A, A244R 0.37 ± 0.2 
S130G <0.1 
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Table 3: Summary of data collection and refinement statistic for the N186Ala -BlaC-EC19 
Complex 
 
  
Data Collection statistics: 
X-Ray Source NSLS Beamline X-29 
Date of Collection 2013-09-20 
Wavelength (Å) 1.0 (Single Wavelength) 
Temperature (K) 100 
Resolution Range 38.5-1.40 
Reflection 50722 
Completeness 91.67 (100) 
Redundancy 6.5 
I/Sigma (σ) 3.05 
Space Group P212121 
Unit Cell (Å)  
A 43.26 
B 71.42 
C 84.68 
α=β=ϒ 90.00° 
Molecules per a.u. 1 
Refinement  
Refinement Program PHENIX  
Rwork (%) 16.60 
Rfree (%) 20.20 
Rfree Test Set 1993 Reflections (4.13%) 
Estimated Twining Fraction No Twining to report 
Atoms  
Total number of Atoms 2341 
Average B Factor 20.0 
Protein (Chain A) 2005 
Phosphate (Chain P)  35 
EC19 (Chain E) 38 
Water (Chain W) 263 
r.m.s. Deviation  
Bond Length (Å) 0.006 
Bond Angle ( °) 1.283 
 
PDB Accession Code 4X6T 
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Scheme 1: Mechanism of Boronic acid Transition State Inhibitors. The top row shows the 
formation of the tetrahedral high-energy intermediate of the cefotaxime-hydrolysis reaction. The 
bottom row shows the boronate complex formation of a cefotaxime-BATSI which resembles the 
tetrahedral high-energy intermediate. 
Scheme 2: General scheme for the synthesis of BATSI compounds. See references in Table 1 
and supplementary information for details. 
Figure 1: The structures and inhibition constants of the compounds tested as inhibitors of BlaC. 
Figure 2: Crystal structure of BlaC with EC19 bound at the active site. Inhibitor atoms are 
colored by atom type. (A) Structure of EC19 (left) and EC19 modelled into the Fo-Fc omit map 
contoured at 2.0 σ. (B) Electrostatic interactions between covalently bound EC19 and BlaC.  
 
Figure 3: Proposed mode of binding of EC19 with BlaC in solution. Only a modest rotation of 
the methylene group connecting the boron atom and the meta-benzoic acid substituent results in 
two hydrogen bonds formed to the side chain of Arg220 and Thr235. 
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Scheme 1:  
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Figure 1 
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Figure 1 (continued) 
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Figure 2 
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Figure 3 
 
 
 
 
Page 25 of 25
ACS Paragon Plus Environment
ACS Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
